Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer

Garrido, C; Manoogian, M; Ghambire, D; Lucas, S; Karnoub, M; Olson, MT; Hicks, DG; Tozbikian, G; Prat, A; Ueno, NT; Modi, S; Feng, WQ; Pugh, J; Hsu, C; Tsurutani, J; Cameron, D; Harbeck, N; Fang, QJ; Khambata-Ford, S; Liu, XM; Inge, LJ; Vitazka, P

Garrido, C (通讯作者)，Daiichi Sankyo Inc, Basking Ridge, NJ 07920 USA.;Manoogian, M (通讯作者)，Roche Tissue Diagnost, Tucson, AZ 85745 USA.

VIRCHOWS ARCHIV, 2023; ():

Abstract

In DESTINY-Breast04 (DB-04), safety and efficacy of HER2-targeted antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) in previously treated H......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索